Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses
CA 2055041 A1 · Owner: Dana-Farber Cancer Institute · Inventors: Pardee, Arthur B.; Novick, William J. Jr.; Dezube, Bruce J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A family of compounds effective in inhibiting replication of a human retrovirus is comprised of 7-(oxoalkyl) 1,3dialkyl xanthines of the formula:, (I) in which R1 and R2 are the same or different and are selected from the group consisting of straight-chain or branched alkyl radicals with 2 to 6 carbon atoms, cyclohexyl alkoxyalkyl, and hydroxyalkyl radicals and A represents a hydrocarbon, radical with up to 4 carbon atoms which can be substituted by a methyl group. Another family of effective compounds is comprised of compounds of the formula: (II), wherein at least one of R1 and R3 is either a ) a branched hydroxyalkyl group of the formula in which R4 stands for an alkyl group with 1 to 3 …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 6, 1991. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 6, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 6, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.